These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 17350337)
1. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Webster-Gandy JD; How C; Harrold K Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337 [TBL] [Abstract][Full Text] [Related]
2. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468 [TBL] [Abstract][Full Text] [Related]
3. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment]. Risum S; Langer SW Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412 [TBL] [Abstract][Full Text] [Related]
4. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868 [TBL] [Abstract][Full Text] [Related]
5. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Lassere Y; Hoff P Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880 [TBL] [Abstract][Full Text] [Related]
6. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932 [TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788 [TBL] [Abstract][Full Text] [Related]
10. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Markman M; Kulp B; Peterson G Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208 [TBL] [Abstract][Full Text] [Related]
11. [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. Bartal A; Mátrai Z; Szûcs A; Liszkay G Magy Onkol; 2011 Jun; 55(2):91-8. PubMed ID: 21655474 [TBL] [Abstract][Full Text] [Related]
12. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217 [TBL] [Abstract][Full Text] [Related]
13. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience. Rossi D; Catalano G Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894 [No Abstract] [Full Text] [Related]